Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L- glutamate for imaging xC - transporter using positron emission tomography in patients with non-small cell lung or breast cancer

Sora Baek, Chang Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong, Jin Sook Ryu, Seung Jun Oh, Claudia Bacher-Stier, Lüder Fels, Norman Koglin, Christina Hultsch, Christoph A. Schatz, Ludger M. Dinkelborg, Erik Mittra, Sanjiv S. Gambhir, Dae Hyuk Moon

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Purpose: (4S)-4-(3-[18F]fluoropropyl)-L-glutamate (BAY 94-9392, alias [18F]FSPG) is a new tracer to image xC - transporter activity with positron emission tomography (PET). We aimed to explore the tumor detection rate of [18F]FSPG in patients relative to 2-[18F]fluoro-2-deoxyglucose ([18F]FDG). The correlation of [18F]FSPG uptake with immunohistochemical expression of x C - transporter and CD44, which stabilizes the xCT subunit of system xC -, was also analyzed. Experimental Design: Patients with non-small cell lung cancer (NSCLC, n = 10) or breast cancer (n = 5) who had a positive [18F]FDG uptake were included in this exploratory study. PET images were acquired following injection of approximately 300 MBq[18F]FSPG. Immunohistochemistry was done using xCT- and CD44-specific antibody. Results: [18F]FSPG PET showed high uptake in the kidney and pancreas with rapid blood clearance. [18F]FSPG identified all 10 NSCLC and three of the five breast cancer lesions that were confirmed by pathology. [18F]FSPG detected 59 of 67 (88%) [ 18F]FDG lesions in NSCLC, and 30 of 73 (41%) in breast cancer. Seven lesions were additionally detected only on [18F]FSPG in NSCLC. The tumor-to-blood pool standardized uptake value (SUV) ratio was not significantly different from that of [18F]FDG in NSCLC; however, in breast cancer, it was significantly lower (P < 0.05). The maximum SUV of [ 18F]FSPG correlated significantly with the intensity of immunohistochemical staining of xC - transporter and CD44 (P < 0.01). Conclusions: [18F]FSPG seems to be a promising tracer with a relatively high cancer detection rate in patients with NSCLC. [ 18F]FSPG PET may assess xC - transporter activity in patients with cancer.

Original languageEnglish (US)
Pages (from-to)5427-5437
Number of pages11
JournalClinical Cancer Research
Volume18
Issue number19
DOIs
StatePublished - Oct 1 2012
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Non-Small Cell Lung Carcinoma
Positron-Emission Tomography
Clinical Trials
Breast Neoplasms
Neoplasms
Pancreas
Research Design
Immunohistochemistry
Pathology
Staining and Labeling
Kidney
Injections
(4S)-4-(3-(18F)fluoropropyl)-L-glutamate
Antibodies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L- glutamate for imaging xC - transporter using positron emission tomography in patients with non-small cell lung or breast cancer. / Baek, Sora; Choi, Chang Min; Ahn, Sei Hyun; Lee, Jong Won; Gong, Gyungyub; Ryu, Jin Sook; Oh, Seung Jun; Bacher-Stier, Claudia; Fels, Lüder; Koglin, Norman; Hultsch, Christina; Schatz, Christoph A.; Dinkelborg, Ludger M.; Mittra, Erik; Gambhir, Sanjiv S.; Moon, Dae Hyuk.

In: Clinical Cancer Research, Vol. 18, No. 19, 01.10.2012, p. 5427-5437.

Research output: Contribution to journalArticle

Baek, S, Choi, CM, Ahn, SH, Lee, JW, Gong, G, Ryu, JS, Oh, SJ, Bacher-Stier, C, Fels, L, Koglin, N, Hultsch, C, Schatz, CA, Dinkelborg, LM, Mittra, E, Gambhir, SS & Moon, DH 2012, 'Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L- glutamate for imaging xC - transporter using positron emission tomography in patients with non-small cell lung or breast cancer', Clinical Cancer Research, vol. 18, no. 19, pp. 5427-5437. https://doi.org/10.1158/1078-0432.CCR-12-0214
Baek, Sora ; Choi, Chang Min ; Ahn, Sei Hyun ; Lee, Jong Won ; Gong, Gyungyub ; Ryu, Jin Sook ; Oh, Seung Jun ; Bacher-Stier, Claudia ; Fels, Lüder ; Koglin, Norman ; Hultsch, Christina ; Schatz, Christoph A. ; Dinkelborg, Ludger M. ; Mittra, Erik ; Gambhir, Sanjiv S. ; Moon, Dae Hyuk. / Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L- glutamate for imaging xC - transporter using positron emission tomography in patients with non-small cell lung or breast cancer. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 19. pp. 5427-5437.
@article{ba3febaabdeb45baa74771baa9c029a7,
title = "Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L- glutamate for imaging xC - transporter using positron emission tomography in patients with non-small cell lung or breast cancer",
abstract = "Purpose: (4S)-4-(3-[18F]fluoropropyl)-L-glutamate (BAY 94-9392, alias [18F]FSPG) is a new tracer to image xC - transporter activity with positron emission tomography (PET). We aimed to explore the tumor detection rate of [18F]FSPG in patients relative to 2-[18F]fluoro-2-deoxyglucose ([18F]FDG). The correlation of [18F]FSPG uptake with immunohistochemical expression of x C - transporter and CD44, which stabilizes the xCT subunit of system xC -, was also analyzed. Experimental Design: Patients with non-small cell lung cancer (NSCLC, n = 10) or breast cancer (n = 5) who had a positive [18F]FDG uptake were included in this exploratory study. PET images were acquired following injection of approximately 300 MBq[18F]FSPG. Immunohistochemistry was done using xCT- and CD44-specific antibody. Results: [18F]FSPG PET showed high uptake in the kidney and pancreas with rapid blood clearance. [18F]FSPG identified all 10 NSCLC and three of the five breast cancer lesions that were confirmed by pathology. [18F]FSPG detected 59 of 67 (88{\%}) [ 18F]FDG lesions in NSCLC, and 30 of 73 (41{\%}) in breast cancer. Seven lesions were additionally detected only on [18F]FSPG in NSCLC. The tumor-to-blood pool standardized uptake value (SUV) ratio was not significantly different from that of [18F]FDG in NSCLC; however, in breast cancer, it was significantly lower (P < 0.05). The maximum SUV of [ 18F]FSPG correlated significantly with the intensity of immunohistochemical staining of xC - transporter and CD44 (P < 0.01). Conclusions: [18F]FSPG seems to be a promising tracer with a relatively high cancer detection rate in patients with NSCLC. [ 18F]FSPG PET may assess xC - transporter activity in patients with cancer.",
author = "Sora Baek and Choi, {Chang Min} and Ahn, {Sei Hyun} and Lee, {Jong Won} and Gyungyub Gong and Ryu, {Jin Sook} and Oh, {Seung Jun} and Claudia Bacher-Stier and L{\"u}der Fels and Norman Koglin and Christina Hultsch and Schatz, {Christoph A.} and Dinkelborg, {Ludger M.} and Erik Mittra and Gambhir, {Sanjiv S.} and Moon, {Dae Hyuk}",
year = "2012",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-12-0214",
language = "English (US)",
volume = "18",
pages = "5427--5437",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L- glutamate for imaging xC - transporter using positron emission tomography in patients with non-small cell lung or breast cancer

AU - Baek, Sora

AU - Choi, Chang Min

AU - Ahn, Sei Hyun

AU - Lee, Jong Won

AU - Gong, Gyungyub

AU - Ryu, Jin Sook

AU - Oh, Seung Jun

AU - Bacher-Stier, Claudia

AU - Fels, Lüder

AU - Koglin, Norman

AU - Hultsch, Christina

AU - Schatz, Christoph A.

AU - Dinkelborg, Ludger M.

AU - Mittra, Erik

AU - Gambhir, Sanjiv S.

AU - Moon, Dae Hyuk

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Purpose: (4S)-4-(3-[18F]fluoropropyl)-L-glutamate (BAY 94-9392, alias [18F]FSPG) is a new tracer to image xC - transporter activity with positron emission tomography (PET). We aimed to explore the tumor detection rate of [18F]FSPG in patients relative to 2-[18F]fluoro-2-deoxyglucose ([18F]FDG). The correlation of [18F]FSPG uptake with immunohistochemical expression of x C - transporter and CD44, which stabilizes the xCT subunit of system xC -, was also analyzed. Experimental Design: Patients with non-small cell lung cancer (NSCLC, n = 10) or breast cancer (n = 5) who had a positive [18F]FDG uptake were included in this exploratory study. PET images were acquired following injection of approximately 300 MBq[18F]FSPG. Immunohistochemistry was done using xCT- and CD44-specific antibody. Results: [18F]FSPG PET showed high uptake in the kidney and pancreas with rapid blood clearance. [18F]FSPG identified all 10 NSCLC and three of the five breast cancer lesions that were confirmed by pathology. [18F]FSPG detected 59 of 67 (88%) [ 18F]FDG lesions in NSCLC, and 30 of 73 (41%) in breast cancer. Seven lesions were additionally detected only on [18F]FSPG in NSCLC. The tumor-to-blood pool standardized uptake value (SUV) ratio was not significantly different from that of [18F]FDG in NSCLC; however, in breast cancer, it was significantly lower (P < 0.05). The maximum SUV of [ 18F]FSPG correlated significantly with the intensity of immunohistochemical staining of xC - transporter and CD44 (P < 0.01). Conclusions: [18F]FSPG seems to be a promising tracer with a relatively high cancer detection rate in patients with NSCLC. [ 18F]FSPG PET may assess xC - transporter activity in patients with cancer.

AB - Purpose: (4S)-4-(3-[18F]fluoropropyl)-L-glutamate (BAY 94-9392, alias [18F]FSPG) is a new tracer to image xC - transporter activity with positron emission tomography (PET). We aimed to explore the tumor detection rate of [18F]FSPG in patients relative to 2-[18F]fluoro-2-deoxyglucose ([18F]FDG). The correlation of [18F]FSPG uptake with immunohistochemical expression of x C - transporter and CD44, which stabilizes the xCT subunit of system xC -, was also analyzed. Experimental Design: Patients with non-small cell lung cancer (NSCLC, n = 10) or breast cancer (n = 5) who had a positive [18F]FDG uptake were included in this exploratory study. PET images were acquired following injection of approximately 300 MBq[18F]FSPG. Immunohistochemistry was done using xCT- and CD44-specific antibody. Results: [18F]FSPG PET showed high uptake in the kidney and pancreas with rapid blood clearance. [18F]FSPG identified all 10 NSCLC and three of the five breast cancer lesions that were confirmed by pathology. [18F]FSPG detected 59 of 67 (88%) [ 18F]FDG lesions in NSCLC, and 30 of 73 (41%) in breast cancer. Seven lesions were additionally detected only on [18F]FSPG in NSCLC. The tumor-to-blood pool standardized uptake value (SUV) ratio was not significantly different from that of [18F]FDG in NSCLC; however, in breast cancer, it was significantly lower (P < 0.05). The maximum SUV of [ 18F]FSPG correlated significantly with the intensity of immunohistochemical staining of xC - transporter and CD44 (P < 0.01). Conclusions: [18F]FSPG seems to be a promising tracer with a relatively high cancer detection rate in patients with NSCLC. [ 18F]FSPG PET may assess xC - transporter activity in patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=84866926512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866926512&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-0214

DO - 10.1158/1078-0432.CCR-12-0214

M3 - Article

VL - 18

SP - 5427

EP - 5437

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19

ER -